AVI-4015 is under clinical development by Avixgen and currently in Phase I for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase I drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVI-4015’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AVI-4015 overview

AVI-4015 is under development for the treatment of keratoconjunctivitis sicca (dry eye). It is administered through ophthalmic route in the form of eye drops. The drug candidate is a repositioning drug acts by targeting DDR1 receptor and is developed based on advanced cell-penetrating peptide (ACP), that delivers the therapeutic drug.

Avixgen overview

Avixgen is a Pharmaceuticals and Healthcare company that offers health care services like therapies and medications for virus infections. The company is Headquartered in Gwanak-gu, Seoul, Republic of Korea (South Korea).

For a complete picture of AVI-4015’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.